 |
|
|
| |
Islatravir Efficacy and Safety for Selected Demographic and
Baseline Subgroups From a Phase 2 Trial In Treatment-naïve
Adults With HIV-1 Infection
|
| |
| |
17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
J-M Molina1; Y Yazdanpanah2; A Afani Saud3; C Bettacchi4; C Chahin Anania5; E DeJesus6; SO Klopfer7; A Grandhi7; K Eves7; MN Robertson7;
Correll T7; C Hwang7; G Hanna7; P Sklar7
1St-Louis Hospital and University, Department of Infectious Disease, Paris, France; 2Bichat Hospital, Paris, France; 3University of
Chile, Santiago, Chile; 4North Texas Infectious Diseases Consultants, Dallas, TX, USA; 5Hospital Hernán Henríquez Aravena of
Temuco, Temuco, Chile; 6Orlando Immunology Center, Orlando, FL, USA; 7Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
